Isavuconazole: A new broad-spectrum azole. Part 1: In vitro activity

被引:29
作者
Denis, J. [1 ]
Ledoux, M. -P. [2 ]
Nivoix, Y. [3 ]
Herbrecht, R. [2 ,4 ]
机构
[1] Univ Strasbourg, Hop Univ, FMTS, Serv Parasitol Mycol,Plateau Tech Microbiol, Strasbourg, France
[2] Univ Hosp Strasbourg, Dept Hematol & Oncol, F-67098 Strasbourg, France
[3] Univ Hosp Strasbourg, Pharm, Strasbourg, France
[4] Univ Strasbourg, INSERM, UMR S1113, IRFAC, 3 Ave Moliere, F-67200 Strasbourg, France
来源
JOURNAL DE MYCOLOGIE MEDICALE | 2018年 / 28卷 / 01期
关键词
Aspergillus; Mucorales; Candida; Isavuconazole; Voriconazole; Susceptibility test; 8 ANTIFUNGAL DRUGS; EPIDEMIOLOGIC CUTOFF VALUES; FRAGMENT LENGTH POLYMORPHISM; BROTH MICRODILUTION METHOD; CRYPTOCOCCUS-NEOFORMANS; SUSCEPTIBILITY PROFILES; ASPERGILLUS-FUMIGATUS; MOLECULAR CHARACTERIZATION; EUROPEAN COMMITTEE; MIC DISTRIBUTIONS;
D O I
10.1016/j.mycmed.2018.02.005
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Triazoles compounds are first-line agents for the treatment of invasive fungal diseases. Isavuconazole is the most recent triazole compound, approved in 2015 by the FDA and the EMA to treat invasive aspergillosis and mucormycosis. We reviewed here the in vitro activity of isavuconazole against a vast spectrum of species. Isavuconazole MICs were evaluated using CLSI, EUCAST or Etest methods, with no significant differences between the technics. Low MIC50 and MIC90 (< 1 mu g/mL) were described for isavuconazole against the majority of Candida spp., except for C. glabrata and C. krusei. In vitro activity against Aspergillus spp. varied according to the species with an overall MIC90 of 1 mu g/mL ranging from 0.125 mu g/mL (A. fumigatus) to 16 mu g/mL (A. niger, A. tubingiensis). As for Aspergillus, the activity of isavuconazole against agents of mucormycosis varies upon genus and species, with an overall MIC90 from 4 (Rhizopus spp.) to 16 mu g/mL (Rhizomucor spp. and Mucor spp.). Recently, to help detecting non wild-type isolates, EUCAST committee has proposed ECOFFs values for C. albicans, C. parapsilosis and C. tropicalis (0.03 mu g/mL), for Aspergillus fumigatus (2 g/mL), A. nidulans (0.25 mu g/mL), A. terreus (1 mu g/mL), A. flavus (2 mu g/mL) and A. niger (4 mu g/mL). Moreover, clinical breakpoints (susceptible/resistant) were defined for Aspergillus fumigatus (1 mu g/mL), A. nidulans (0.25 mu g/mL) and A. terreus (1 mu g/mL). Using these breakpoints, isavuconazole showed activity against the vast majority of fungi. (C) 2018 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:8 / 14
页数:7
相关论文
共 62 条
[1]   Specific antifungal susceptibility profiles of opportunists in the Fusarium fujikuroi complex [J].
Al-Hatmi, Abdullah M. S. ;
van Diepeningen, Anne D. ;
Curfs-Breuker, Ilse ;
de Hoog, G. Sybren ;
Meis, Jacques F. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2015, 70 (04) :1068-1071
[2]   Impact of Treatment Strategy on Outcomes in Patients with Candidemia and Other Forms of Invasive Candidiasis: A Patient-Level Quantitative Review of Randomized Trials [J].
Andes, David R. ;
Safdar, Nasia ;
Baddley, John W. ;
Playford, Geoffrey ;
Reboli, Annette C. ;
Rex, John H. ;
Sobel, Jack D. ;
Pappas, Peter G. ;
Kullberg, Bart Jan .
CLINICAL INFECTIOUS DISEASES, 2012, 54 (08) :1110-1122
[3]  
[Anonymous], ANTIMICROB AGENTS CH
[4]   EUCAST technical note on isavuconazole breakpoints for Aspergillus, itraconazole breakpoints for Candida and updates for the antifungal susceptibility testing method documents [J].
Arendrup, M. C. ;
Meletiadis, J. ;
Mouton, J. W. ;
Guinea, J. ;
Cuenca-Estrella, M. ;
Lagrou, K. ;
Howard, S. J. .
CLINICAL MICROBIOLOGY AND INFECTION, 2016, 22 (06) :571.e1-571.e4
[5]   In Vitro Activity of Isavuconazole and Comparators against Clinical Isolates of the Mucorales Order [J].
Arendrup, Maiken Cavling ;
Jensen, Rasmus Hare ;
Meletiadis, Joseph .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (12) :7735-7742
[6]   EUCAST Testing of Isavuconazole Susceptibility in Aspergillus: Comparison of Results for Inoculum Standardization Using Conidium Counting versus Optical Density [J].
Arendrup, Maiken Cavling ;
Howard, Susan ;
Lass-Floerl, Cornelia ;
Mouton, Johan W. ;
Meletiadis, Joseph ;
Cuenca-Estrella, Manuel .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2014, 58 (11) :6432-6436
[7]   Evaluation of the in vitro activity of isavuconazole and comparator voriconazole against 2635 contemporary clinical Candida and Aspergillus isolates [J].
Astvad, K. M. T. ;
Hare, K. ;
Arendrup, M. C. .
CLINICAL MICROBIOLOGY AND INFECTION, 2017, 23 (11) :882-887
[8]   Microdilution in vitro antifungal susceptibility of Exophiala dermatitidis, a systemic opportunist [J].
Badali, H. ;
de Hoog, G. S. ;
Sudhadham, M. ;
Meis, J. F. .
MEDICAL MYCOLOGY, 2011, 49 (08) :819-824
[9]   In Vitro Susceptibility Profiles of Eight Antifungal Drugs against Clinical and Environmental Strains of Phaeoacremonium [J].
Badali, Hamid ;
Khodavaisy, Sadegh ;
Fakhim, Hamed ;
de Hoog, G. Sybren ;
Meis, Jacques F. ;
Chowdhary, Anuradha .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (12) :7818-7822
[10]   Use of Amplified Fragment Length Polymorphism To Identify 42 Cladophialophora Strains Related to Cerebral Phaeohyphomycosis with In Vitro Antifungal Susceptibility [J].
Badali, Hamid ;
de Hoog, G. Sybren ;
Curfs-Breuker, Ilse ;
Klaassen, Corne H. W. ;
Meis, Jacques F. .
JOURNAL OF CLINICAL MICROBIOLOGY, 2010, 48 (07) :2350-2356